1-溴-4-[4-(三氟甲基)苯氧基]苯 | 137736-26-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4-[4-(三氟甲基)苯氧基]苯
• 英文名称: 1-bromo-4-(4-(trifluoromethyl)phenoxy)benzene
• 英文别名: 1-bromo-4-[4-(trifluoromethyl)phenoxy]benzene
• CAS: 137736-26-6
• 化学式: C₁₃H₈BrF₃O
• 分子量: 317.105
• InChiKey: KTHNGROTROUDLO-UHFFFAOYSA-N

物化性质

• 沸点：
  94-96 °C(Press: 0.15 Torr)
• 密度：
  1.512±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-溴-4-[4-(三氟甲基)苯氧基]苯 在 四(三苯基膦)钯 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 氢溴酸 、 potassium acetate 、 potassium carbonate 、 溶剂黄146 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 60.0h， 生成 6-chloro-7-methoxy-2-methyl-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)quinolin-4(1H)-one
  参考文献：
  名称：

  Discovery, Synthesis, and Optimization of Antimalarial 4(1H)-Quinolone-3-Diarylethers

  摘要：

  The historical antimalarial compound endochin served as a structural lead for optimization. Endochin-like quinolones (ELQ) were prepared by a novel chemical route and assessed for in vitro activity against multidrug resistant strains of Plasmodium falciparum and against malaria infections in mice. Here we describe the pathway to discovery of a potent class of orally active antimalarial 4(1H)-quinolone-3-diarylethers. The initial prototype, ELQ-233, exhibited low nanomolar IC50 values against all tested strains including clinical isolates harboring resistance to atovaquone. ELQ-271 represented the next critical step in the iterative optimization process, as it was stable to metabolism and highly effective in vivo. Continued analoging revealed that the substitution pattern on the benzenoid ring of the quinolone core significantly influenced reactivity with the host enzyme. This finding led to the rational design of highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to established antimalarials chloroquine and atovaquone.

  DOI：

  10.1021/jm500147k
• 作为产物：
  描述：

  4-溴苯酚 、 4-三氟甲基苯硼酸 在 copper diacetate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以97%的产率得到1-溴-4-[4-(三氟甲基)苯氧基]苯
  参考文献：
  名称：

  Copper Mediated Formation of Carbon-Heteroatom Bonds Using Organoboron Reagents and Ultrasound

  摘要：

  This report summarizes research efforts focused on copper acetate mediated reactions to form new carbon-heteroatom bonds using organoboron reagents under ultrasound irradiation. The method involves the application of ultrasound irradiation to the Chan-Evans-Lam reaction to achieve O-arylation of phenols, N-arylation of anilines and indoles, and S-arylation of thiols. Ultrasound irradiation was found to decrease reaction times from 72 hours to 4 hours while improving the product yields an average of 20%(1) Representative C-O, C-N, and C-S coupling reactions were successfully scaled-up from the milligram to gram levels while maintaining good product yields offering potential applications in industrial processes.

  DOI：

  10.3987/com-14-s(k)18

文献信息

• Synthesis and Structure–Activity Relationships of 4-Pyridones as Potential Antimalarials
  作者：Clive L. Yeates、John F. Batchelor、Edward C. Capon、Neil J. Cheesman、Mitch Fry、Alan T. Hudson、Mary Pudney、Helen Trimming、James Woolven、José M. Bueno、Jesús Chicharro、Esther Fernández、José M. Fiandor、Domingo Gargallo-Viola、Federico Gómez de las Heras、Esperanza Herreros、María L. León

  DOI：10.1021/jm0705760

  日期：2008.5.1

  A series of diaryl ether substituted 4-pyridones have been identified as having potent antimalarial activity superior to that of chloroquine against Plasmodium falciparum in vitro and murine Plasmodium yoelii in vivo. These were derived from the anticoccidial drug clopidol through a systematic study of the effects of varying the side chain on activity. Relative to clopidol the most active compounds

  已鉴定出一系列二芳基醚取代的4-吡啶酮，其在体外和体内对鼠恶性疟原虫的有效抗疟活性优于氯喹对恶性疟原虫的抗疟活性。这些是通过对侧链变化对活性的影响进行系统研究而从抗球虫药clopidol衍生而来的。相对于氯吡咯醇，最具活性的化合物在体外抑制恶性疟原虫的IC50改善了500倍以上，而在小鼠中相对于针对约氏疟原虫的ED50则提高了约100倍。这些化合物已在其他地方显示出通过抑制细胞色素bc1络合物处线粒体电子传递的作用而选择性发挥作用。
• [EN] AZASPIRO[4.5] DECANE DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS D'AZASPIRO[4.5] DÉCANE ET LEUR UTILISATION
  申请人：PURDUE PHARMA LP

  公开号：WO2015031036A1

  公开（公告）日：2015-03-05

  The invention provides azaspiro[4.5]decane derivatives of Formula (A): and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, wherein A1, X, A2, Rr, R2', W1, W2, R3', R4', a, and b are defined in the disclosure. The invention also provides compounds of Formulae I, and B-G, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof. Further, the invention provides use of the compounds of Formulae A-G and I, and the pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, to treat pain. In certain embodiments, Compounds of the Disclosure are useful for treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了具有公式（A）的氮杂螺[4.5]癸烷衍生物及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体，其中A1、X、A2、Rr、R2'、W1、W2、R3'、R4'、a和b在本文中有定义。本发明还提供了具有公式I和B-G的化合物以及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体。此外，本发明还提供了使用公式A-G和I的化合物以及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体，用于治疗疼痛的方法。在某些实施例中，本文所述的化合物对于治疗对一种或多种钠通道阻滞有反应的疾病是有用的。
• Heterocyclic compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0447164A1

  公开（公告）日：1991-09-18

  A compound of formula (I):- wherein R¹ represents a hydrogen or halogen atom, or a cyano group; R² represents an optionally substituted carbocyclic group having 6 to 10 ring atoms and containing at least one aromatic ring; an optionally substituted heterocyclic group having 5 to 10 ring atoms, including 1 to 4 heteroatoms selected from O,N and S, and containing at least one aromatic ring; or an optionally substituted C₃₋₆cycloalkyl, C₃₋₆cycloalkyl- C₁₋₆alkyl, or C₁₋₁₀alkyl group; R³ and R⁴, which may be the same or different, each represent    a hydrogen or halogen atom, or a C₁₋₆alkyl group optionally substituted by 1 to 3 halogen atoms; and R⁵ represents    a hydrogen atom, a hydroxyl group, or a C₁₋₆alkyl group, optionally substituted by hydroxy, carboxy, amino or mono- or di-(C₁₋₄)alkyl amino,    and salts and other physiologically functional derivative thereof. The compounds are useful in the treatment of parasitic infections eg. malaria, coccidiosis and Pneumocystis carinii pneumonia.

  化合物的化学式为（I）：其中R¹代表氢原子或卤素原子或氰基；R²代表可选取代的碳环基团，其有6至10个环原子并含有至少一个芳香环；可选取代的杂环基团，其有5至10个环原子，包括1至4个从O、N和S中选取的杂原子，并含有至少一个芳香环；或可选取代的C₃₋₆环烷基、C₃₋₆环烷基- C₁₋₆烷基，或C₁₋₁₀烷基；R³和R⁴，它们可以相同也可以不同，每个代表氢原子或卤素原子，或由1至3个卤素原子取代的C₁₋₆烷基；R⁵代表氢原子、羟基，或由羟基、羧基、氨基或单烷基或双烷基(C₁₋₄)氨基取代的C₁₋₆烷基，以及其盐和其他生理功能衍生物。这些化合物在治疗寄生虫感染，例如疟疾、球虫病和肺孢子虫肺炎中有用。
• AZASPIRO[4.5] DECANE DERIVATIVES AND USE THEREOF
  申请人：PURDUE PHARMA L.P.

  公开号：US20160207923A1

  公开（公告）日：2016-07-21

  The invention provides azaspiro[4.5]decane derivatives of Formula (A): and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, wherein A 1 , X, A 2 , Rr, R 2′ , W 1 , R 3′ , R 4′ , a, and b are defined in the disclosure. The invention also provides compounds of Formulae I, and B-G, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof. Further, the invention provides use of the compounds of Formulae A-G and I, and the pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, to treat pain. In certain embodiments, Compounds of the Disclosure are useful for treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了式（A）的氮杂螺[4.5]癸烷衍生物，以及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体，其中A1、X、A2、Rr、R2'、W1、R3'、R4'、a和b在文献中有定义。本发明还提供了式I和B-G的化合物，以及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体。此外，本发明提供了使用式A-G和I的化合物，以及其药学上可接受的盐、溶剂化合物、水合物、N-氧化物和对映体，用于治疗疼痛。在某些实施例中，本文所述的化合物可用于治疗对一种或多种钠通道阻滞敏感的疾病。
• Azaspiro[4.5]decane derivatives and use thereof
  申请人：Purdue Pharma L.P.

  公开号：US11180502B2

  公开（公告）日：2021-11-23

  The invention provides azaspiro[4.5]decane derivatives of Formula (A): and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, wherein A1, X, A2, Rr, R2′, W1, W2, R3′, R4′, a, and b are defined in the disclosure. The invention also provides compounds of Formulae I, and B-G, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof. Further, the invention provides use of the compounds of Formulae A-G and I, and the pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, to treat pain. In certain embodiments, Compounds of the Disclosure are useful for treating a disorder responsive to blockade of one or more sodium channels.

  本发明提供了式(A)的氮杂螺[4.5]癸烷衍生物：及其药学上可接受的盐、溶液剂、水合物、N-氧化物和非对映异构体，其中A1、X、A2、Rr、R2′、W1、W2、R3′、R4′、a和b在公开中定义。本发明还提供了式 I 和 B-G 的化合物及其药学上可接受的盐、溶液剂、水合物、N-氧化物和非对映异构体。此外，本发明还提供了式 A-G 和 I 的化合物及其药学上可接受的盐、溶液剂、水合物、N-氧化物和非对映异构体治疗疼痛的用途。在某些实施方案中，本发明公开的化合物可用于治疗对阻断一种或多种钠通道有反应的疾病。